Supplementary Information

Ruthenium(IV) porphyrin catalyzed phosphoramidation of aldehyde with phosphoryl azide as nitrene source

Wenbo Xiao, Cong-Ying Zhou and Chi-Ming Che*

Department of Chemistry, State Key Laboratory of Synthetic Chemistry, and Open Laboratory of Chemical Biology of the Institute of Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong, Pokfulam Road, Hong Kong, China.

Fax: (852) 2857-1586 Tel: (852) 2859-2154 E-mail: cmche@hku.hk

Table of contents	S1
I. General Information	S2
II. Synthesis of Ruthenium(IV) Porphyrins	S2
III. Synthesis of Phosphoryl Azides	S2
IV. General procedure for the phosphoramidation of aldehyde with phosphoryl azide catalyzed by $[Ru^{IV}(TTP)Cl_2]$	S4
V. Procedure for the Scale-up Synthesis	S4
VI. Kinetic Isotope Effect Experiment	S5
VII. Characterizations of Products	S6
NMR Spectra	S20

I. General Information

Unless otherwise stated, all reactions were performed under argon atmosphere. DPPA and aldehydes were obtained commercially and used without further purification unless acid impurities were identified in aldehydes. Molecular sieves were dried at 400°C for 3 h prior to use. All solvents were purified by distillation using standard methods. Metal porphyrins and organic azides were synthesized according to previously reported methods. All ¹H NMR and ¹³C NMR spectra were recorded on Bruker AV300 or AV400 NMR spectrometers with tetramethylsilane (TMS) as internal reference. ³¹P NMR spectra were recorded on Bruker AV400 NMR spectrometer with 85% H₃PO₄ as external reference. Mass spectra were recorded on Finnigan MAT 95 mass spectrometer. Elemental analysis was conducted on Flash EA 1112 analyzer by Analysis & Test Center of Institute of Chemistry of Chinese Academy of Sciences. *Caution!* Organic azides are potentially explosive and should be handled with great care.

II. Synthesis of Ruthenium(IV) Porphyrins

Ruthenium(IV) porphyrins were synthesized according to the following references.

[Ru^{IV}(TDCPP)Cl₂] J.-L. Zhang and C.-M. Che, *Chem. Eur. J.*, 2005, **11**, 3899.

[Ru^{IV}(TTP)Cl₂] W.-H., Leung, T. S. M. Hun, H.-w. Hou, K.-Y. Wong, *J. Chem. Soc.*, *Dalton Trans.* 1997, 237.

III. Synthesis of Phosphoryl Azides

Dimethyl phosphorazidate **3b**, diethyl phosphorazidate **3c** and bis(2, 2, 2-trichloroethyl) phosphorazidate **3d** were prepared according to the literature with minor modification.

General procedure for the synthesis of phosphoryl azides:

To a stirred solution of phosphorochloridate (3 mmol) in acetone (20 mL), was added sodium azide (4.5 mmol) in one portion at room temperature. The reaction mixture was stirred for 3h, during this period white solid precipitated. Then the mixture was filtered through a short celite, washed with 20ml of acetone. The filtrate was dried by a rotary evaporator at room temperature with a foil cover on the flask to prevent from light. The residue was purified by column chromatography (silica gel, DCM) to give pure product.

Bis(2, 2, 2-trichloroethyl) phosphorazidate 3d

White solid, 78% yield.

¹H NMR (CDCl₃,400MHz): δ4.71-4.65(m, 4H); ¹³C NMR (CDCl₃,100MHz): δ94.2, 94.1, 77.5, 77.5; ³¹P NMR (CDCl₃,162MHz): δ-2.3(s); HRMS(EI) m/z Calcd. for C4H4Cl6N3O3P [M]⁺ 382.8121, found 382.8103.

References for the synthesis of phosphoryl azides:

S. H. Kim, D. Y. Jung and S. Chang, *J. Org. Chem.*, 2007, **72**, 9769

3c

T. Shioiri and S. Yamada, *Chem. Pharm. Bull.*,1974, **22**, 855

3e

IV. General procedure for the phosphoramidation of aldehyde with phosphoryl azide catalyzed by $[Ru^{IV}(TTP)Cl_2]$

To an oven-dried schlenk flask with a rubber seal was added aldehyde (0.2mmol), DPPA (0.24 mmol), 3ÅMS (25 mg) and [Ru^{IV}(TTP)Cl₂] (5 mmol%). The flask was evacuated and backfilled with argon three times. Freshly distilled dichloromethane (1 mL) was added via syringe. The reaction mixture was stirred under reflux for 12h. After cooled down to room temperature, the reaction mixture was filtered through a short celite. The filtrate was concentrated by a rotary evaporator and purified by column chromatography (silica gel, DCM) to give pure product.

V. Procedure for the Scale-up Synthesis

To an oven-dried schlenk flask was added [Ru^{IV}(TTP)Cl₂] (42 mg, 0.05 mmol, 5 mol%) and 125 mg of 3Å molecular sieve. The sealed flask was degassed for 20min and backfilled with argon. The freshly distilled DCM (3 mL) and *p*-anisaldehyde (136 mg, 1 mmol, 1 equiv.) were added via syringe. The mixture was heated to reflux. A solution of DPPA (330 mg, 1.2 mmol, 1.2 equiv.) in 2.5 mL of DCM was added dropwise via syringe pump within 5h. After addition, the reaction mixture was stirred for another 7h. Then the reaction mixture was concentrated by a rotary evaporator and the residue was purified by column chromatography to give the pure product **2c** in 92% yield.

VI. Kinetic Isotope Effect Experiment

To an oven-dried schlenk flask with a rubber seal was added bis(2,2,2-trichloroethyl) phosphorazidate **3d** (77 mg, 0.2 mmol), [Ru^{IV}(TTP)Cl₂] (8.4 mg, 0.01 mmol, 5 mol%) and 50 mg of 3Å molecular sieve. The flask was evacuated and backfilled with argon three times. Then benzaldehyde **1b** (32 mg, 0.3 mmol) and benzaldehyde-d6 **1p** (34 mg, 0.3 mmol) were added. The reaction mixture was stirred under reflux for 12h. Upon the completion of the reaction, the mixture was allowed to cool and purified by a column chromatography (silica gel, hexane:EA=3:1) to give a mixture of bis(2,2,2-trichloroethyl) benzoylphosphoramidate **2t** and bis(2,2,2-trichloroethyl) benzoylphosphoramidate-d5 **2u** (the labile D of N-D was replaced by H during purification). The ratio of k_H/k_D was determined by 1 H NMR.

VII. Characterizations of Products

Diphenyl (4-methylbenzoyl)phosphoramidate 2a

¹H NMR (CDCl₃,400MHz): δ9.49(d, 1H, NH, $J_{\text{H-P}}$ =10.3Hz), 7.86(d, 2H, J=7.8Hz), 7.25-7.22(m, 8H), 7.18(d, 2H, J=7.9Hz), 7.14-7.11(m, 2H), 2.38(s, 3H); ¹³C NMR (CDCl₃,100MHz): δ167.5(d, C5, $J_{\text{C-P}}$ =3.6Hz), 150.2(C4 or C4'), 150.1(C4 or C4'), 143.8, 129.8(C2 & C2'), 129.5(d, C6, $J_{\text{C-P}}$ =11.4Hz), 129.3, 128.5, 125.6(C1 & C1'), 120.7(C3 or C3'), 120.6(C3 or C3'), 21.7; ³¹P NMR (CDCl₃,162MHz): δ-9.1(d, $J_{\text{P-H}}$ =10.3Hz).

HRMS(EI) m/z Calcd. for C20H18NO4P [M]⁺ 367.0973, found 367.0957.

Diphenylbenzoylphosphoramidate 2b

¹H NMR (CDCl₃,400MHz): δ9.62(d, 1H, NH, $J_{\text{H-P}}$ =9.6Hz), 7.97(d, 2H, J=8.6Hz), 7.54(t, 1H, J=7.4Hz), 7.39(t, 2H, J=7.8Hz), 7.25(m, 8H), 7.17-7.11(m, 2H); ¹³C NMR (CDCl₃,100MHz): δ167.6(d, C5, $J_{\text{C-P}}$ =3.4Hz), 150.2(C4 or C4'), 150.1(C4 or C4'), 133.1, 132.3(d, C6, $J_{\text{C-P}}$ =11.2Hz), 129.8(C2 & C2'), 128.6, 128.5,

125.7(C1 & C1'), 120.6(C3 or C3'), 120.6(C3 or C3'); 31 P NMR (CDCl₃,162MHz): δ -9.1(d, J_{P-H} =9.6Hz).

HRMS(EI) m/z Calcd. for C19H16NO4P [M]⁺ 353.0817, found 353.0810.

Anal. Calcd. for C19H16NO4P: C, 64.59; H, 4.56; N, 3.96. Found: C, 64.59; H, 4.52; N, 3.92.

Diphenyl (4-methoxybenzoyl)phosphoramidate 2c

¹H NMR (CDCl₃,400MHz): $\delta 8.79$ (d, 1H, NH, $J_{\text{H-P}}$ =10.3Hz), 7.90(d, 2H, J=8.9Hz), 7.28-7.26(m, 8H), 7.17-7.13(m, 2H), 6.88(d, 2H, J=8.9Hz), 3.85(s, 3H); ¹³C NMR (CDCl₃,100MHz): $\delta 167.0$ (d, C5, $J_{\text{C-P}}$ =3.2Hz), 163.5 (C-OMe), 150.3(C4 or C4'), 150.2(C4 or C4'), 131.1, 129.8(C2 & C2'), 125.6(C1 & C1'), 124.6(d, C6, $J_{\text{C-P}}$ =11.3Hz), 120.7(C3 or C3'), 120.6(C3 or C3'), 113.8, 55.6; ³¹P NMR (CDCl₃,162MHz): $\delta -8.8$ (d, $J_{\text{P-H}}$ =10.3Hz).

HRMS(EI) m/z Calcd. for C20H18NO5P [M]⁺ 383.0923, found 383.0912.

Anal. Calcd. for C20H18NO5P: C, 62.66; H, 4.73; N, 3.65. Found: C, 62.07; H, 4.71; N, 3.74.

Diphenyl (4-hydroxybenzoyl)phosphoramidate 2d

¹H NMR (*d*6-DMSO,400MHz): δ10.41(s, 1H), 10.37(s, 1H), 7.87(d, 2H, J=8.4Hz), 7.45(t, 4H, J=7.3Hz), 7.29-7.27(m, 6H), 6.85(d, 2H, J=7.9Hz); ¹³C NMR (*d*6-Acetone,100MHz): δ167.5 (C5), 162.7 (C-OH), 151.5(C4 or C4'), 151.4(C4 or C4'), 131.4, 130.6(C2 & C2'), 126.2(C1 & C1'), 124.8(d, C6, J_{C-P}=11.1Hz), 121.5(C3 or C3'), 121.4(C3 or C3'), 116.1; ³¹P NMR (CDCl₃,162MHz): δ-9.7(s).

HRMS(EI) m/z Calcd. for C19H16NO5P [M]⁺ 369.0766, found 369.0748.

Anal. Calcd. for C19H16NO5P: C, 61.79; H, 4.37; N, 3.79. Found: C, 61.78; H, 4.39; N, 3.73.

Diphenylbenzo[d][1,3]dioxole-5-carbonylphosphoramidate 2e

¹H NMR (CDCl₃,400MHz): δ9.58(d, 1H, NH, $J_{\text{H-P}}$ =10.1Hz), 7.56(dd, 1H, J=8.2, 1.8Hz), 7.50(d, 1H, J=1.7Hz), 7.25-7.21(m, 8H), 7.15-7.13(m, 2H), 6.72(d, 1H, J=8.2Hz), 6.02(s, 2H); ¹³C NMR (CDCl₃,100MHz): δ166.7(d, C5, $J_{\text{C-P}}$ =3.1Hz), 151.7(C-O-dioxolane), 150.2(C4 or C4'), 150.1(C4 or C4'), 148.1(C-O-dioxolane), 129.8(C2 & C2'), 126.3(d, C6, $J_{\text{C-P}}$ =11.3Hz), 125.7(C1 & C1'), 124.3,

120.6(C3 or C3'), 120.6(C3 or C3'), 108.8, 108.1, 101.9(O-CH₂-O); 31 P NMR (CDCl₃,162MHz): δ-9.0(d, J_{P-H} =9.9Hz).

HRMS(EI) m/z Calcd. for C20H16NO6P [M]⁺ 397.0715, found 397.0708.

Diphenyl(4-chlorobenzoyl)phosphoramidate 2f

¹H NMR (CDCl₃,400MHz): δ9.65(d, 1H, NH, $J_{\text{H-P}}$ =10.1Hz), 7.88(d, 2H, J=8.6Hz), 7.32(d, 2H, J=8.5Hz), 7.27-7.19(m, 8H), 7.15-7.13(m, 2H); ¹³C NMR (CDCl₃,75MHz): δ166.6(d, C5, $J_{\text{C-P}}$ =3.3Hz), 150.2(C4 or C4′), 150.1(C4 or C4′), 139.6(C-Cl), 130.6(d, C6, $J_{\text{C-P}}$ =11.4Hz), 130.0, 129.9(C2 & C2′), 128.9, 125.8(C1 or C1′), 125.8(C1 or C1′), 120.6(C3 or C3′), 120.5(C3 or C3′); ³¹P NMR (CDCl₃,162MHz): δ-9.2(d, $J_{\text{P-H}}$ =9.9Hz).

HRMS(EI) m/z Calcd. for C19H15ClNO4P [M]⁺ 387.0427, found 387.0417.

Anal. Calcd. for C19H15ClNO4P: C, 58.85; H, 3.90; N, 3.61. Found: C, 58.38; H, 3.84; N, 3.68.

Diphenyl (4-nitrobenzoyl)phosphoramidate 2g

¹H NMR (CDCl₃,400MHz): δ10.22(d, 1H, NH, $J_{\text{H-P}}$ =9.4Hz), 8.16(d, 2H, J=8.6Hz), 8.11(d, 2H, J=8.8Hz), 7.28(t, 4H, J=7.9Hz), 7.20-7.16(m,6H); ¹³C NMR (CDCl₃, 75MHz): δ166.2 (d, C5, $J_{\text{C-P}}$ =3.2Hz), 150.9(C-NO₂), 150.5(C4 or C4'), 150.4(C4 or C4'), 137.8(d, C6, $J_{\text{C-P}}$ =11.7Hz), 130.4(C2 & C2'), 130.2, 126.5(C1 or C1'), 126.5(C1 or C1'), 124.2, 120.9(C3 or C3'), 120.9(C3 or C3'); ³¹P NMR (CDCl₃,162MHz): δ-9.7(d, $J_{\text{P-H}}$ =9.4Hz).

HRMS(EI) m/z Calcd. for C19H15N2O6P [M]⁺ 398.0668, found 398.0658.

Anal. Calcd. for C19H15N2O6P: C, 57.29; H, 3.80; N, 7.03. Found: C, 57.30; H, 3.87; N, 6.94.

Diphenyl 2-naphthoylphosphoramidate 2h

¹H NMR (CDCl₃,400MHz): δ10.00(d, 1H, NH, $J_{\text{H-P}}$ =10.2Hz), 8.61(s, 1H), 8.06(dd, 1H, J=8.6, 1.7Hz), 7.85(d, 1H, J=8.0Hz), 7.84(d, 1H, J=8.6Hz), 7.72(d, 1H, J=8.0Hz), 7.58(t, 1H, J=7.0Hz), 7.49(t, 1H, J=7.1Hz), 7.27-7.15(m, 8H), 7.08(t, 2H, J=7.1Hz); ¹³C NMR (CDCl₃,100MHz): δ167.8(d, C5, $J_{\text{C-P}}$ =3.4Hz), 150.2(C4 or C4'), 150.1(C4 or C4'), 135.5, 132.5, 129.9, 129.8(C2 & C2'), 129.6, 129.4(d, C6, $J_{\text{C-P}}$ =11.2Hz), 128.5, 128.4, 127.7, 126.8, 125.6(C1 & C1'), 124.5, 120.7(C3 or C3'), 120.6(C3 or C3'); ³¹P NMR (CDCl₃,162MHz): δ-8.8(d, $J_{\text{P-H}}$ =9.9Hz).

HRMS(EI) m/z Calcd. for C23H18NO4P [M]⁺ 403.0973, found 403.0964.

Diphenyl furan-2-carbonylphosphoramidate 2i

¹H NMR (CDCl₃,400MHz): δ8.71(d, 1H, NH, $J_{\text{H-P}}$ =10.3Hz), 7.48(dd, 1H, H9, $J_{\text{H9-H8}}$ =1.7Hz, $J_{\text{H9-H7}}$ =0.7Hz), 7.31(d, 1H, H7, $J_{\text{H7-H8}}$ =3.6Hz), 7.28-7.26(m, 8H), 7.18-7.15(m, 2H), 6.48(dd, 1H, H8, $J_{\text{H8-H9}}$ =1.7Hz, $J_{\text{H8-H7}}$ =3.6Hz); ¹³C NMR (CDCl₃,100MHz): δ165.4 (C5), 157.4 (C6), 150.1(C4 or C4'), 150.0(C4 or C4'), 146.1(C9), 129.8(C2 & C2'), 125.7(C1 & C1'), 120.6(C3 or C3'), 120.6(C3 or C3'), 117.7(C7), 112.7(C8); ³¹P NMR (CDCl₃,162MHz): δ-10.7(d, $J_{\text{P-H}}$ =10.1Hz).

HRMS(EI) m/z Calcd. for C17H14NO5P [M]⁺ 343.0610, found 343.0599.

Anal. Calcd. for C17H14NO5P: C, 59.48; H, 4.11; N, 4.08. Found: C, 59.54; H, 4.12; N, 4.03.

Diphenylcinnamoylphosphoramidate 2j

¹H NMR (CDCl₃,400MHz): δ9.21(d, 1H, NH, $J_{\text{H-P}}$ =11.5Hz), 7.73(d, 1H, J_{trans} =15.8Hz), 7.46(d, 1H, $J_{\text{=}}$ 7.12Hz), 7.45(d, 1H, $J_{\text{=}}$ 7.64Hz), 7.39-7.36(m, 3H), 7.28-7.23(m, 8H), 7.15-7.14(m, 2H), 6.46(d, 1H, J_{trans} =15.7Hz); ¹³C NMR (CDCl₃,100MHz): δ166.4 (C5), 150.1(C4 or C4'), 150.0(C4 or C4'), 144.8 (C7), 134.2(C8), 130.6, 129.9(C2 & C2'), 129.0, 128.4, 125.8(C1 & C1'), 120.6(C3 or

C3'), 120.6(C3 or C3'), 119.4(d, C6, $J_{C-P}=12.9$ Hz); ³¹P NMR (CDCl₃, 162MHz): δ -8.8(d, $J_{P-H}=11.2$ Hz).

HRMS(EI) m/z Calcd. for C21H18NO4P [M]⁺ 379.0973, found 379.0956.

Anal. Calcd. for C21H18NO4P: C, 66.49; H, 4.78; N, 3.69. Found: C, 66.46; H, 4.76; N, 3.68.

Diphenyl (3-methylbut-2-enoyl)phosphoramidate 2k

¹H NMR (CDCl₃,400MHz): δ8.66(d, 1H, NH, $J_{\text{H-P}}$ =11.3Hz), 7.31-7.21(m,8H), 7.19-7.15(m,2H), 5.61(s, 1H), 2.17(s, 3H), 1.83(s, 3H); ¹³C NMR (CDCl₃,100MHz): δ166.3(d, C5, $J_{\text{C-P}}$ =2.6Hz), 158.4(d, C7, $J_{\text{C-P}}$ =2.4Hz), 150.2(C4 or C4'), 150.1(C4 or C4'), 129.8(C2 & C2'), 125.6(C1 & C1'), 120.7(C3 or C3'), 120.6(C3 or C3'), 117.3(d, C6, $J_{\text{C-P}}$ =12.9Hz), 27.7, 20.5; ³¹P NMR (CDCl₃,162MHz): δ-9.1(d, $J_{\text{P-H}}$ =11.8Hz).

HRMS(EI) m/z Calcd. for C17H18NO4P [M]⁺ 331.0973, found 331.0964.

Diphenyl (5,6-dihydro-2H-pyran-3-carbonyl)phosphoramidate 2l

¹H NMR (CDCl₃,400MHz): δ9.34(d, 1H, NH, $J_{\text{H-P}}$ =10.0Hz), 7.32-7.27(m, 4H), 7.22-7.16(m, 6H), 6.87-6.85(m, 1H), 4.30(dd, 2H, J=4.4, 2.5Hz), 3.68(t, 2H, J=5.5Hz), 2.17-2.11(m,2H); ¹³C NMR (CDCl₃,100MHz): δ166.6(d, C5, $J_{\text{C-P}}$ =3.3Hz), 150.6(C4 or C4'), 150.5(C4 or C4'), 135.9 (C8), 132.5(d, C6, $J_{\text{C-P}}$ =10.4Hz), 130.2(C2 & C2'), 126.1(C1 & C1'), 120.9(C3 or C3'), 120.9(C3 or C3'), 64.8(C7), 63.6, 25.9; ³¹P NMR (CDCl₃,162MHz): δ-9.1(d, $J_{\text{P-H}}$ =9.9Hz).

HRMS(EI) m/z Calcd. for C18H18NO5P [M]⁺ 359.0923, found 359.0911.

Diphenyloctanoylphosphoramidate 2m

$$\begin{array}{c|c}
2' & 1' \\
0 & 4 & 3' \\
\downarrow P - 0 & 3' \\
6 & H & 0 & 3 \\
3 & 2 & 1
\end{array}$$

¹H NMR (CDCl₃,400MHz): δ9.06(d, 1H, NH, $J_{\text{H-P}}$ =11.0Hz), 7.32-7.26(m,4H), 7.21-7.16(m, 6H), 2.19(t, 2H, J=7.3Hz), 1.50(m, 2H), 1.24(m, 8H), 0.88-0.84(m, 3H); ¹³C NMR (CDCl₃,100MHz): δ174.6(d, C5, $J_{\text{C-P}}$ =4.8Hz), 150.1(C4 or C4'), 150.0(C4 or C4'), 129.8(C2 & C2'), 125.7(C1 & C1'), 120.6(C3 or C3'), 120.5(C3 or C3'), 37.2(d, C6, $J_{\text{C-P}}$ =9.5Hz), 31.7, 29.0, 28.9, 24.8, 22.7, 14.1; ³¹P NMR (CDCl₃,162MHz): δ-10.4(d, $J_{\text{P-H}}$ =11.1Hz)

HRMS(EI) m/z Calcd. for C20H26NO4P [M]⁺ 375.1599, found 375.1593.

Anal. Calcd. for C20H26NO4P: C, 63.99; H, 6.98; N, 3.73. Found: C, 64.14; H, 7.07; N, 3.63.

Diphenyl (3-phenylpropanoyl)phosphoramidate 2n

¹H NMR (CDCl₃,400MHz): δ9.15(d, 1H, NH, $J_{\text{H-P}}$ =11.4Hz), 7.25-7.11(m, 15H), 2.84(t, 2H, J=7.7Hz), 2.50(t, 2H, J=7.7Hz); ¹³C NMR (CDCl₃,100MHz): δ173.58(d, C5, $J_{\text{C-P}}$ =4.8Hz), 150.0(C4 or C4′), 149.9(C4 or C4′), 140.3(C8), 129.8(C2 & C2′), 128.5, 128.5, 126.3, 125.7(C1 & C1′), 120.6(C3 or C3′), 120.5(C3 or C3′), 38.6(d, C6, $J_{\text{C-P}}$ =9.9Hz), 30.5(C7); ³¹P NMR (CDCl₃,162MHz): δ-9.8(d, $J_{\text{P-H}}$ =11.6Hz).

HRMS(EI) m/z Calcd. for C21H20NO4P [M]⁺ 381.1130, found 381.1118.

Diphenyl (1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbonyl)-phosphoramidate 20

¹H NMR (CDCl₃,400MHz): δ10.30(d, 1H, NH, $J_{\text{H-P}}$ =14.0Hz), 7.52(t, 2H, J=7.5Hz), 7.47(t, 1H, J=7.4Hz), 7.30-7.27(m, 10H), 7.16-7.13(m,2H), 3.33(s, 3H), 2.70(s, 3H); ¹³C NMR (CDCl₃,100MHz): δ163.9(C5), 163.1(C8), 154.9(C7), 150.6(C4 or C4'), 150.5(C4 or C4'), 132.7(C9), 129.9, 129.7(C2 & C2'), 129.5, 127.0, 125.3(C1 & C1'), 120.8(C3 or C3'), 120.7(C3 or C3'), 98.3(d,

C6, J_{C-P} =12.5Hz), 33.4(N-CH₃), 12.1; ³¹P NMR (CDCl₃,162MHz): δ-10.3(d, J_{P-H} =13.9Hz).

HRMS(EI) m/z Calcd. for C24H22N3O5P [M]⁺ 463.1297, found 463.1285.

Dimethyl (4-methylbenzoyl)phosphoramidate 2p

¹H NMR (CDCl₃,400MHz): δ9.01(d, 1H, NH, $J_{\text{H-P}}$ =9.1Hz), 7.96(d, 2H, J=6.7Hz), 7.28(d, 2H, J=6.8Hz), 3.91(s, 3H), 3.88(s, 3H), 2.41(s, 3H); ¹³C NMR (CDCl₃,100MHz): δ167.9(d, C2, $J_{\text{C-P}}$ =2.0Hz), 143.8(C4), 129.6(d, C3, $J_{\text{C-P}}$ =10.5Hz) 129.4, 128.4, 54.6(C1 or C1'), 54.5(C1 or C1'), 21.7; ³¹P NMR (CDCl₃,162MHz): δ1.8(d, $J_{\text{P-H}}$ =9.6Hz).

HRMS(EI) m/z Calcd. for C10H14NO4P [M]⁺ 243.0660, found 243.0649.

Anal. Calcd. for C10H14NO4P: C, 49.39; H, 5.80; N, 5.76. Found: C, 49.09; H, 5.78; N, 5.61.

Diethyl (4-methylbenzoyl)phosphoramidate 2q

¹H NMR (CDCl₃,400MHz): δ8.83(d, 1H, NH, $J_{\text{H-P}}$ =9.0Hz), 7.93(d, 2H, J=8.2Hz), 7.27(d, 2H, J=7.9Hz), 4.34-4.20(m, 4H), 2.41(s, 3H), 1.37(t, 6H, J=7.0Hz); ¹³C NMR (CDCl₃,100MHz): δ167.4(C3), 143.3(C5), 129.6(d, C4, $J_{\text{C-P}}$ =10.4Hz), 129.1, 128.0, 64.0(C2 or C2'), 63.9(C2 or C2'), 21.3, 15.9(C1 or C1'), 15.8(C1 or C1'); ³¹P NMR (CDCl₃,162MHz): δ-1.5(q, $J_{\text{P-H}}$ =8.0Hz).

HRMS(EI) m/z Calcd. for C12H18NO4P [M]⁺ 271.0973, found 271.0968.

Bis(2,2,2-trichloroethyl) (4-methylbenzoyl)phosphoramidate 2r

¹H NMR (CDCl₃,400MHz): δ9.46(d, 1H, NH, $J_{\text{H-P}}$ =10.1Hz), 7.94(d, 2H, J=8.1Hz), 7.27(d, 2H, J=7.7Hz), 4.84(s, 2H), 4.82(s,2H), 2.42(s,3H); ¹³C NMR (CDCl₃,75MHz): δ168.2(C3), 144.5(C5), 129.7, 128.8(d, C4, $J_{\text{C-P}}$ =10.9Hz), 128.5, 94.8(C1 or C1'), 94.7(C1 or C1'), 77.9(C2 or C2'), 77.9(C2 or C2'), 21.8; ³¹P NMR (CDCl₃,162MHz): δ-3.7(q, $J_{\text{P-H}}$ = 7.9Hz).

HRMS(EI) m/z Calcd. for C12H12Cl6NO4P [M]⁺ 474.8635, found 474.8626.

Anal. Calcd. for C12H12Cl6NO4P: C, 30.16; H, 2.53; N, 2.93. Found: C, 30.33; H, 2.59; N, 3.04.

Bis(4-nitrophenyl) (4-methylbenzoyl)phosphoramidate 2s

¹H NMR (CDCl₃,400MHz): δ8.97(s, 1H, NH), 8.18(d, 4H, J=8.4Hz), 7.81(d, 2H, J=7.9Hz), 7.42(d, 4H, J=8.7Hz), 7.25(d, 2H, J=7.5Hz), 2.43(s,3H); ¹³C NMR (CDCl₃,100MHz): δ161.7 (C5), 154.2(C4 or C4'), 154.2(C4 or C4'), 145.6(C6), 145.3(C1 & C1'), 129.8, 128.3, 126.3, 125.9(C2 & C2'), 121.4(C3 or C3'), 121.3(C3 or C3'), 115.8, 21.7; ³¹P NMR (CDCl₃,162MHz): δ-10.4(s).

Bis(2,2,2-trichloroethyl) benzoylphosphoramidate 2t

¹H NMR (CDCl₃,400MHz): δ9.49(d, 1H, NH, $J_{\text{H-P}}$ =8.6Hz), 8.05(d, 2H, J=7.5Hz), 7.60(t, 1H, J=7.4Hz), 7.48(t, 2H, J=7.6Hz), 4.85(s,2H), 4.83(s,2H); ¹³C NMR (CDCl₃,100MHz):δ168.2(C3), 133.5, 131.5(d, C4, $J_{\text{C-P}}$ =10.9Hz), 128.8, 128.3, 94.6(C1 or C1'), 94.5(C1 or C1'), 77.8(C2 or C2'), 77.8(C2 or C2'); ³¹P NMR (CDCl₃,162MHz): δ-3.8(m).

HRMS(EI) m/z Calcd. for C11H10C6NO4P [M]⁺ 460.8479, found 460.8468.

X-Ray Data of Diphenyl(4-methylbenzoyl)phosphoramidate 2a




Fig. S1 X-ray crystal structure of 2a (CCDC 862823 for 2a contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from

The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif).

Computing details

Program(s) used to solve structure: *SHELXS97* (Sheldrick, 2008); program(s) used to refine structure: *SHELXL97* (Sheldrick, 2008).

Crystal data

$C_{20}H_{18}NO_4P$	F(000) = 768

$$M_r = 367.32$$
 $D_x = 1.294 \text{ Mg m}^{-3}$

Monoclinic,
$$P2_1/n$$
 Cu $K\alpha$ radiation, $\lambda = 1.54178 \text{ Å}$

$$a = 10.0023$$
 (7) Å Cell parameters from 216 reflections

$$b=10.6631(7)\text{Å}$$
 $\theta=3-45^{\circ}$

$$c=17.6975(12)\text{Å}$$
 $\mu=1.50\text{mm}^{-1}$

$$\beta = 92.303(2)^{\circ}$$
 $T = 296K$

$$V=1886.0(2)$$
Å³ Block, Yellow

$$Z=4$$
 0.04×0.04×0.03mm

Data collection

Radiation source: fine-focus sealed 3061reflectionswith $I > 2\sigma(I)$

tube

graphite $R_{\text{int}}=0.047$

Absorption correction: Multi-scan

$$\theta_{\text{max}} = 65.9^{\circ}, \theta_{\text{min}} = 4.8^{\circ}$$

$$T_{\min} = 0.942, T_{\max} = 0.956$$
 $h = -11 \rightarrow 10$

23806measuredreflections	$k=-12\rightarrow 12$

3232independentreflections
$$l=-20\rightarrow 20$$

Refinement

Refinement on F^2 Primary atom site location: Structure-

invariant direct methods

Least-square smatrix: Full Secondary atom site location: Difference

Fourier map

 $R[F^2>2\sigma(F^2)]=0.038$ Hydrogen site location: Inferred from

neighbouring sites

 $wR(F^2)=0.109$ H-atom parameters constrained

S=1.04 $w=1/[\sigma^2(F_0^2)+(0.0697P)^2+0.352P]$

where $P = (F_0^2 + 2F_c^2)/3$


3232 reflections $(\Delta/\sigma)_{max} = 0.002$


236 parameters $\Delta \rho_{max} \!\!=\!\! 0.18 e \mathring{A}^{-3}$

0 restraints $\Delta \rho_{min} \!\!=\!\! -0.44 e \mathring{A}^{-3}$


NMR Spectra


Bis(2,2,2-trichloroethyl)phosphorazidate3d







Diphenyl (4-methylbenzoyl)phosphoramidate 2a










Diphenylbenzoylphosphoramidate 2b










Diphenyl (4-methoxybenzoyl)phosphoramidate 2c










Diphenyl (4-hydroxybenzoyl)phosphoramidate 2d










Diphenylbenzo[d][1,3]dioxole-5-carbonylphosphoramidate 2e










Diphenyl(4-chlorobenzoyl)phosphoramidate 2f










Diphenyl (4-nitrobenzoyl)phosphoramidate 2g










Diphenyl 2-naphthoylphosphoramidate 2h










Diphenyl furan-2-carbonylphosphoramidate 2i













Diphenylcinnamoylphosphoramidate 2j










Diphenyl (3-methylbut-2-enoyl)phosphoramidate 2k










Diphenyl (5,6-dihydro-2H-pyran-3-carbonyl)phosphoramidate 2l










Diphenyloctanoylphosphoramidate 2m










Diphenyl (3-phenylpropanoyl)phosphoramidate 2n










Diphenyl (1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carbonyl)-phosphoramidate 20










Dimethyl (4-methylbenzoyl)phosphoramidate 2p










Diethyl (4-methylbenzoyl)phosphoramidate 2q










Bis(2,2,2-trichloroethyl) (4-methylbenzoyl)phosphoramidate 2r





Bis(4-nitrophenyl) (4-methylbenzoyl)phosphoramidate 2s





Bis(2,2,2-trichloroethyl) benzoylphosphoramidate 2t

